Xpression Atlas, the largest gene and fusion panel, is now a part of Afirma GSC. TERT DNA analysis is now also available
Learn More
You should use your device in portrait mode
Conclusively rule out surgery. Confidently guide treatment.
Afirma® Genomic Sequencing Classifier is a comprehensive solution to help you personalize diagnosis and treatment for your patients with thyroid nodules
Expertise comes with experience – as the gold standard for thyroid molecular analysis, Afirma has helped approximately 250,000 patients avoid unnecessary surgery or personalize treatment plans to avoid overtreatment.1
Thyroid nodule diagnosis is challenging and can create uncertainty
Studies have shown that up to
80% of patients with indeterminate thyroid nodules who undergo surgery without molecular testing are found to be Benign postoperatively19-22
Afirma GSC combines RNA expression analysis of over 10,000 genes with advanced machine learning to provide:
a Benign result that can be trusted to conclusively rule out surgery
or
a suspicious result with information on the presence/absence of molecular variant/fusions to confidently guide treatment
Afirma GSC provides a clinically actionable Benign vs Suspicious result,
allowing you to conclusively rule out surgery for the majority of your patients with an indeterminate nodule3
Real world performance
Meta-analysis of 13 independent studies assessing Afirma’s performance in diverse clinical settings16

  • 97%

    Sensitivity

  • 99%

    NPV

  • 65%

    PPV

    significantly better than validation16

  • 67%

    Benign call rate

Clinically validated through a prospective, blinded, multicenter study published in JAMA surgery3
Validation study showed 96% sensitivity, 91% NPV, and 47% PPV
Hürthle/Oncocytic performance
Afirma GSC leverages a combination of mRNA expression, mitochondrial transcripts, and chromosomal level loss of heterozygosity to reclassify significantly more Hürthle/oncocytic cell lesions as Benign6,7.9-11

89% Sensitivity in classifying
Hürthle/oncocytic cells3-5

~3 in 4
Hürthle/oncocytic cell dominant nodules
resulted in Afirma GSC Benign6,7,9-11

The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
Real world performance
Meta-analysis of 13 independent studies assessing Afirma’s performance in diverse clinical settings16

  • 97%

    Sensitivity

  • 99%

    NPV

  • 65%

    PPV

    significantly better than validation16

  • 67%

    Benign call rate

Clinically validated through a prospective, blinded, multicenter study published in JAMA surgery3
Validation study showed 96% sensitivity, 91% NPV, and 47% PPV
Hürthle/Oncocytic performance
Afirma GSC leverages a combination of mRNA expression, mitochondrial transcripts, and chromosomal level loss of heterozygosity to reclassify significantly more Hürthle/oncocytic cell lesions as Benign6,7.9-11

89% Sensitivity in classifying
Hürthle/oncocytic cells3-5

~3 in 4
Hürthle/oncocytic cell dominant nodules
resulted in Afirma GSC Benign6,7,9-11

The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
The impact of Afirma GSC on 100 patients with B-III/IV nodules
For Afirma GSC Suspicious or cytologically suspicious/malignant nodules, Afirma GSC identifies actionable variants/fusions,
allowing you to confidently guide personalized treatment decisions2
Prevalence of variant/fusion positive findings

  • 44%

    of GSC Suspicious2

  • 64%

    of Bethesda V2

  • 86%

    of Bethesda VI2

  • Largest thyroid gene and fusion panel available1
  • Clinically validated and informed by The Cancer Genome Atlas, published literature, and Veracyte R&D discovery using nearly 40,000 samples1,14
  • 593 genes, 905 variants, 235 fusions
  • Expression signature data associated with variant/fusion findings are included in the report to help predict tumor behavior14,15
DNA analysis of the TERT promoter region is available for additional diagnostic and prognostic insight on the suspicious nodule
Our mission is to provide accurate molecular insights to help you create the best treatment plan for your patient

Afirma: Count on a simplified experience

  • Veracyte is committed to providing patient access, regardless of financial situation
    • Covered by Medicare1
    • Covered in-network by most commercial payers (over 275 million covered lives)1
    • The Veracyte Access Program supports both eligible uninsured and commercially insured patients with financial need1
  • Get answers quickly, reduce worry and wait1
  • Easily manage patient reports with the Veracyte portal and mobile app
    • Access the Veracyte portal at portal.veracyte.com
  • Easily manage patient reports with the Veracyte mobile app
    • Download the Veracyte app from your mobile app store
Our mission is to provide accurate molecular insights to help you create the best treatment plan for your patient

Afirma: Count on a simplified experience

  • Veracyte is committed to providing patient access, regardless of financial situation
    • Covered by Medicare1
    • Covered in-network by most commercial payers (over 275 million covered lives)1
    • The Veracyte Access Program supports both eligible uninsured and commercially insured patients with financial need1
  • Get answers quickly, reduce worry and wait1
  • Easily manage patient reports with the Veracyte portal and mobile app
    • Access the Veracyte portal at portal.veracyte.com
  • Easily manage patient reports with the Veracyte mobile app
    • Download the Veracyte app from your mobile app store